Agnitio Science and Technology, Inc. signed a non-exclusive license agreement for COVID-19(SARS-CoV2) antibodies detection
May25, 2020.
Agnitio Science and Technology, Inc. (Agnitio) signed a non-exclusive license agreement with Taiwan's top research institute, Academia Sinica, on May 18. Academia Sinica provides biomaterials for manufacturing COVID-19 antibodiesdetection by Agnitio. Meanwhile, EUA (Emergency Use Authorizations) application of BioIC SARS-CoV2 IgG/IgM Detection Kit is submitted to Taiwan FDA, Ministry of Health and Welfare.
Established in Hsinchu Science Park, Taiwan, in 2001, Agnitio has successfully developed BioIC®, an immunoassay platform, by integrating proprietary microfluidic technology and chemiluminescence technology. This platform technology provides different panels of localallergen s-IgEantibodies test for years.
Different from traditional rapid test, BioIC SARS-CoV2 IgG/IgM Detection Kit uses automated microfluidic technology and chemiluminescence technology. The test report is generated in about 25 minutes.
The immunoassay has a high sensitivity of 0.62ng / mL. In addition to SARS-CoV2, BioIC SARS-CoV2 IgG/IgM Detection Kit can also provide information of antibodies, such as coronaviruses OC43, NL63 and other widely circulating human-infecting coronaviruses, known to cause common cold symptoms. People infected by any one of these viruses may produce antibodies that cross-react with antibodies produced in response to infection with SARS-CoV2.In the test of COVID-19 patients, BioIC SARS-VoV2 IgG/IgM Detection Kit shows particularly good results: 100% specificity andsensitivity. In order to provide optimized products, Agnitio is licensed the biomaterial of 7 human-infecting coronaviruses.
